Search results for: hospital

Collaborating at the Leadership Level: Q&A with Lisa Fitzgerald, MD, & George Tsokos, MD

Carina Stanton | May 1, 2020

Rheumatology leaders are adapting to telemedicine and other modified collaborations to adjust patient care and research during the COVID-19 pandemic…

Transitioning to a Virtual Practice: Q&A with Lisa Criscione-Schreiber, MD, MEd

Carina Stanton | May 1, 2020

A quick shift to virtual teaching and patient care is just one of many changes rheumatologists at Duke University are adapting to during the COVID-19 pandemic…

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein | May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Fear & Hope in the Era of the Modern Plague

Jose U. Scher, MD | April 29, 2020

This plague has affected each one of us, our families and friends, and abruptly, it has altered the way we relate to one another.

3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome

Julie Steenhuysen | April 29, 2020

CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…

Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

Deena Beasley | April 27, 2020

(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…

U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Reuters Staff | April 27, 2020

(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…